Field investigation of high reported non-neonatal tetanus burden in Uganda, 2016-2017.


Journal

International journal of epidemiology
ISSN: 1464-3685
Titre abrégé: Int J Epidemiol
Pays: England
ID NLM: 7802871

Informations de publication

Date de publication:
08 2023
Historique:
received: 06 03 2022
accepted: 27 01 2023
medline: 4 8 2023
pubmed: 11 2 2023
entrez: 10 2 2023
Statut: ppublish

Résumé

Despite providing tetanus-toxoid-containing vaccine (TTCV) to infants and reproductive-age women, Uganda reports one of the highest incidences of non-neonatal tetanus (non-NT). Prompted by unusual epidemiologic trends among reported non-NT cases, we conducted a retrospective record review to see whether these data reflected true disease burden. We analysed nationally reported non-NT cases during 2012-2017. We visited 26 facilities (14 hospitals, 12 health centres) reporting high numbers of non-NT cases (n = 20) or zero cases (n = 6). We identified non-NT cases in facility registers during 1 January 2016-30 June 2017; the identified case records were abstracted. During 2012-2017, a total of 24 518 non-NT cases were reported and 74% were ≥5 years old. The average annual incidence was 3.43 per 100 000 population based on inpatient admissions. Among 482 non-NT inpatient cases reported during 1 January 2016-30 June 2017 from hospitals visited, 342 (71%) were identified in facility registers, despite missing register data (21%). Males comprised 283 (83%) of identified cases and 60% were ≥15 years old. Of 145 cases with detailed records, 134 (92%) were clinically confirmed tetanus; among these, the case-fatality ratio (CFR) was 54%. Fourteen cases were identified at two hospitals reporting zero cases. Among >4000 outpatient cases reported from health centres visited, only 3 cases were identified; the remainder were data errors. A substantial number of non-NT cases and deaths occur in Uganda. The high CFR and high non-NT burden among men and older children indicate the need for TTCV booster doses across the life course to all individuals as well as improved coverage with the TTCV primary series. The observed data errors indicate the need for data quality improvement activities.

Sections du résumé

BACKGROUND
Despite providing tetanus-toxoid-containing vaccine (TTCV) to infants and reproductive-age women, Uganda reports one of the highest incidences of non-neonatal tetanus (non-NT). Prompted by unusual epidemiologic trends among reported non-NT cases, we conducted a retrospective record review to see whether these data reflected true disease burden.
METHODS
We analysed nationally reported non-NT cases during 2012-2017. We visited 26 facilities (14 hospitals, 12 health centres) reporting high numbers of non-NT cases (n = 20) or zero cases (n = 6). We identified non-NT cases in facility registers during 1 January 2016-30 June 2017; the identified case records were abstracted.
RESULTS
During 2012-2017, a total of 24 518 non-NT cases were reported and 74% were ≥5 years old. The average annual incidence was 3.43 per 100 000 population based on inpatient admissions. Among 482 non-NT inpatient cases reported during 1 January 2016-30 June 2017 from hospitals visited, 342 (71%) were identified in facility registers, despite missing register data (21%). Males comprised 283 (83%) of identified cases and 60% were ≥15 years old. Of 145 cases with detailed records, 134 (92%) were clinically confirmed tetanus; among these, the case-fatality ratio (CFR) was 54%. Fourteen cases were identified at two hospitals reporting zero cases. Among >4000 outpatient cases reported from health centres visited, only 3 cases were identified; the remainder were data errors.
CONCLUSIONS
A substantial number of non-NT cases and deaths occur in Uganda. The high CFR and high non-NT burden among men and older children indicate the need for TTCV booster doses across the life course to all individuals as well as improved coverage with the TTCV primary series. The observed data errors indicate the need for data quality improvement activities.

Identifiants

pubmed: 36762894
pii: 7034126
doi: 10.1093/ije/dyad005
pmc: PMC10413815
mid: NIHMS1899980
doi:

Substances chimiques

Tetanus Toxoid 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1150-1162

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Published by Oxford University Press on behalf of the International Epidemiological Association 2023.

Références

Am J Trop Med Hyg. 2017 Feb 8;96(2):415-420
pubmed: 27920395
Bull World Health Organ. 2016 Aug 1;94(8):613-21
pubmed: 27516639
Vaccine. 2020 May 6;38(21):3800-3807
pubmed: 31983584
Springerplus. 2016 Jun 10;5(1):705
pubmed: 27350934
MMWR Morb Mortal Wkly Rep. 2020 May 01;69(17):515-520
pubmed: 32352953
Bull World Health Organ. 2017 Nov 01;95(11):779-783
pubmed: 29147059
MMWR Morb Mortal Wkly Rep. 2016 Jan 22;65(2):36-7
pubmed: 26797167
J Neurol Sci. 2016 Sep 15;368:292-9
pubmed: 27538652
Pan Afr Med J. 2017 Jun 22;27(Suppl 3):24
pubmed: 29296159
Afr Health Sci. 2008 Mar;8(1):61-4
pubmed: 19357737
Wkly Epidemiol Rec. 2011 Dec 9;86(50):565-75
pubmed: 22180897
MMWR Suppl. 2006 Apr 28;55(1):25-30
pubmed: 16645579
PLoS One. 2018 Dec 31;13(12):e0209167
pubmed: 30596676
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S578-85
pubmed: 26553691
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S570-7
pubmed: 26553690
Can J Anaesth. 2009 Apr;56(4):307-15
pubmed: 19296192
World J Emerg Surg. 2011 Jul 08;6:20
pubmed: 21740539
Clin Pediatr (Phila). 1970 Nov;9(11):691-4
pubmed: 5477284
Springerplus. 2016 Jun 27;5(1):892
pubmed: 27386340
BMC Health Serv Res. 2022 Jan 7;22(1):40
pubmed: 34996445
Niger Postgrad Med J. 2004 Jun;11(2):97-102
pubmed: 15300269

Auteurs

Rebecca Mary Casey (RM)

Global Immunization Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Joyce Nguna (J)

Expanded Programme on Immunization, Ministry of Health, Kampala, Uganda.

Bernard Opar (B)

Expanded Programme on Immunization, Ministry of Health, Kampala, Uganda.

Immaculate Ampaire (I)

Expanded Programme on Immunization, Ministry of Health, Kampala, Uganda.

Joseph Lubwama (J)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Kampala, Uganda.

Patricia Tanifum (P)

Global Immunization Division, Centers for Disease Control and Prevention, Kampala, Uganda.

Bao-Ping Zhu (BP)

Division of Global Health Protection, Centers for Disease Control and Prevention, Kampala, Uganda.

Annet Kisakye (A)

World Health Organization, Country Office, Kampala, Uganda.

Eva Kabwongera (E)

UNICEF, Country Office, Kampala, Uganda.

Rania A Tohme (RA)

Global Immunization Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Benjamin A Dahl (BA)

Global Immunization Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Alison D Ridpath (AD)

Global Immunization Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Heather M Scobie (HM)

Global Immunization Division, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH